The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals' Lynozyfic, a therapy for recurrent multiple myeloma, boosting the company's shares by 2%.

Argus downgraded Regeneron Pharmaceuticals from a buy to a hold rating in its latest research report, signaling caution.

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.

Concerns about bribery allegations, angry CBS News staff and a looming high-stakes merger made for tense monthslong negotiations. The travel-review company's shares have fallen after it rejected ...